STK11 and non-small cell lung carcinoma: To enhance the clinical outcomes of PD-1/PD-L1 inhibitor-based therapy for “immune desert environment” NSCLC caused by STK11 and/or KEAP1 mutations, the addition of CTLA-4 inhibitors to PD-1/PD-L1 inhibitors represents a promising approach.